Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Efavirenz

FDA-approved product (capsule, oral), marketed as Efavirenz, Sustiva.

Registered studies
50+
Lab records
0
Pathogens at ≥40%
2 of 4

Chemical structure

Chemical structure of Efavirenz
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • HIV infection
  • HIV-1 infection
  • Immunodeficiency disease
  • Infection
  • Viral disease

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Non-nucleoside reverse transcriptase inhibitors
FDA pharmacologic class
Human Immunodeficiency Virus 1 Non-Nucleoside Analog Reverse Transcriptase Inhibitor FDA label ↗
Anti-infective classification
Classified as another kind of anti-infective (for example an antifungal, antiviral or antiparasitic medicine).WHO ATC J05AG03

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against M. tuberculosis and MRSA. It was surfaced computationally for further investigation; it is not an established treatment for these infections.

AI-predicted activity

AI prediction · nothing measured
  • MRSA51.8% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • E. coli35.8% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae24.0% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis63.9% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Efavirenz in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

-8.2 kcal/mol

0better fit →-12

KPC-2 carbapenemase ↗ (K. pneumoniae)

-7.8 kcal/mol

0better fit →-12

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

-7.5 kcal/mol

0better fit →-12

Dihydrofolate reductase ↗ (MRSA)

-7.4 kcal/mol

0better fit →-12

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Efavirenz with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • Addition of Efavirenz or Nelfinavir to a Lamivudine/Zidovudine/Indinavir HIV Treatment Regimen

    NCT00000903

    Registered record
    Registry ID
    NCT00000903
    Conditions
    HIV Infections
    Interventions
    Indinavir sulfate; Lamivudine/Zidovudine; Nelfinavir mesylate; Efavirenz
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    Not recorded
    Completion
    2001-07
    Enrolment
    444

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHIV Infections
    InterventionIndinavir sulfate; Lamivudine/Zidovudine; Nelfinavir mesylate; Efavirenz
    PhasePhase 3
    Registry statusCompleted

  • A Study of the Effectiveness of Different Anti-HIV Treatments in HIV-Positive Individuals Who Have Been on a Protease Inhibitor-Containing Drug Regimen for at Least 16 Weeks

    NCT00000914

    Registered record
    Registry ID
    NCT00000914
    Conditions
    HIV Infections
    Interventions
    Indinavir sulfate; Ritonavir; Nelfinavir mesylate; Efavirenz
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Completed
    Start
    Not recorded
    Completion
    2000-06
    Enrolment
    800

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHIV Infections
    InterventionIndinavir sulfate; Ritonavir; Nelfinavir mesylate; Efavirenz
    PhaseNot applicable
    Registry statusCompleted

  • A Study to Compare The Ability of Different Anti-HIV Drugs to Decrease Viral Load After Nelfinavir (an Anti-HIV Drug)Treatment Failure

    NCT00000918

    Registered record
    Registry ID
    NCT00000918
    Conditions
    HIV Infections
    Interventions
    Indinavir sulfate; Lamivudine/Zidovudine; Ritonavir; Amprenavir; Efavirenz; Saquinavir; Lamivudine; Stavudine; Zidovudine; Didanosine
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    Not recorded
    Completion
    2002-02
    Enrolment
    300

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHIV Infections
    InterventionIndinavir sulfate; Lamivudine/Zidovudine; Ritonavir; Amprenavir +6 more
    PhasePhase 2
    Registry statusCompleted

  • Changing to Nonprotease Inhibitor Treatment to Improve Side Effects

    NCT00021463

    Registered record
    Registry ID
    NCT00021463
    Conditions
    HIV Infections; Lipodystrophy
    Interventions
    Abacavir sulfate, Lamivudine and Zidovudine; Abacavir sulfate; Efavirenz; Nevirapine
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    Not recorded
    Completion
    Not recorded
    Enrolment
    342

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHIV Infections; Lipodystrophy
    InterventionAbacavir sulfate, Lamivudine and Zidovudine; Abacavir sulfate; Efavirenz; Nevirapine
    PhasePhase 2
    Registry statusCompleted

  • Increasing HAART-Induced Immune Restoration With Cyclosporine

    NCT00031070

    Registered record
    Registry ID
    NCT00031070
    Conditions
    HIV Infections
    Interventions
    Abacavir sulfate, Lamivudine and Zidovudine; Cyclosporine; Hepatitis A Vaccine (Inactivated); Efavirenz; Pneumococcal Conjugate Vaccine, Heptavalent; Rabies Vaccine
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    Not recorded
    Completion
    2006-12
    Enrolment
    40

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHIV Infections
    InterventionAbacavir sulfate, Lamivudine and Zidovudine; Cyclosporine; Hepatitis A Vaccine (Inactivated); Efavirenz +2 more
    PhasePhase 2
    Registry statusCompleted